Vikas Lifecare

Why is Vikas Lifecare Ltd falling/rising?

As of 19-Jul, Vikas Lifecare Ltd's stock price is at 1.34, reflecting a decline of 2.19%. The stock has underperformed significantly, with a year-to-date drop of 24.29% and a 47.86% decrease over the past year, indicating a bearish trend.

As of 19-Jul, Vikas Lifecare Ltd's stock price is falling, currently at 1.34, which reflects a change of -0.03 or -2.19%. The stock has underperformed compared to the benchmark Sensex, which has gained 0.75% over the past week. Over the last week, Vikas Lifecare has seen a decline of 3.60%, and its performance over the past month shows a significant drop of 10.07%. Year-to-date, the stock has decreased by 24.29%, and over the past year, it has fallen by 47.86%. <BR><BR>Additionally, the stock has been on a consecutive decline for the last two days, contributing to the overall negative trend. It is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish sentiment. Although there has been a rise in investor participation, with a delivery volume increase of 69.63% on July 16, this has not translated into positive price movement. Overall, these factors contribute to the ongoing decline in Vikas Lifecare Ltd's stock price.

Which are the latest news on Vikas Lifecare?

Should I buy, sell or hold Vikas Lifecare Ltd?

Are Vikas Lifecare Ltd latest results good or bad?

Vikas Lifecare Ltd's latest results show significant challenges, with a net profit of ₹41.57 crores overshadowed by an operating loss of ₹26.28 crores and a negative cash flow of ₹222 crores, indicating ongoing struggles despite a 73.78% increase in net sales. Overall, the financial health of the company remains concerning.

The latest results for Vikas Lifecare Ltd present a mixed picture, but overall, they indicate significant challenges. In Q4 FY26, the company reported a consolidated net profit of ₹41.57 crores, which might seem positive at first glance. However, this figure is misleading due to a substantial operating loss of ₹26.28 crores, resulting in an operating margin of -15.59%. This marks the lowest operating margin in seven quarters, highlighting severe operational difficulties.<BR><BR>While net sales surged by 73.78% quarter-on-quarter to ₹168.62 crores, this growth did not translate into profitability. The company continues to struggle with negative cash flows and a return on equity of -0.66%, indicating that it is destroying shareholder value rather than creating it. Furthermore, the year-on-year comparison reveals a staggering decline of 1533.45% in net profit compared to Q4 FY25.<BR><BR>The operational challenges are compounded by a negative cash flow from operations of ₹222 crores in FY25, raising concerns about the company's ability to sustain its business model. The volatility in revenues and persistent losses suggest that Vikas Lifecare is facing significant hurdles that could hinder any potential recovery.<BR><BR>In summary, while there are signs of revenue growth, the underlying financial health of Vikas Lifecare Ltd is concerning, leading to the conclusion that the latest results are more indicative of ongoing struggles rather than a turnaround.

What does Vikas Lifecare do?

Vikas Lifecare Ltd specializes in recycling plastic waste and manufacturing polymer compounds, operating as a Micro Cap company. As of December 2025, it reported net sales of 97 Cr and a net loss of 29 Cr.

Overview: <BR>Vikas Lifecare Ltd operates in the recycling of plastic waste and the trading and manufacturing of polymer compounds, positioned within the Trading & Distributors industry and categorized as a Micro Cap company.<BR><BR>History: <BR>Vikas Lifecare Limited was originally incorporated as Vikas Multicorp Limited in 1995. The company underwent a name change to Vikas Lifecare Limited, which was formalized with a Special Resolution and a fresh Certificate of Incorporation issued on April 09, 2021. The latest quarterly results reported net sales and profit for December 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 97 Cr (Quarterly Results - Dec 2025) <BR>Net Profit: -29 Cr (Quarterly Results - Dec 2025) <BR>Market Cap: INR 279 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 14 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.16 <BR>Return on Equity: -0.66% <BR>Price to Book: 0.50<BR><BR>Contact Details: <BR>Address: G 1 34/1 East Punjabi Bagh, Vikas Apartments, New Delhi, Delhi: 110026 <BR>Tel: 91-011-40450110 <BR>Email: info@vikasmulticorp.com <BR>Website: http://www.vikaslifecarelimited.com

How big is Vikas Lifecare?

As of 10th June, Vikas Lifecare Ltd has a market capitalization of 279.00 Cr and reported Net Sales of 465.94 Cr, with a Net Profit loss of 26.06 Cr over the latest 4 quarters. Shareholder's Funds were 531.76 Cr and Total Assets were 724.76 Cr as of March 2025.

As of 10th June, Vikas Lifecare Ltd has a market capitalization of 279.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Vikas Lifecare reported Net Sales of 465.94 Cr. However, the company experienced a loss of 26.06 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 531.76 Cr and Total Assets were reported at 724.76 Cr.

Who are in the management team of Vikas Lifecare?

The management team of Vikas Lifecare includes Arvind Gupta (CFO), Anil Kumar, Ruby Bansal, Parul Rai (Company Secretary), Vijay Kumar Sharma (CEO), Sundeep Kumar Dhawan (Managing Director), Richa Sharma, and Chandan Kumar (Director & CFO), who oversee the company's operations and strategy.

The management team of Vikas Lifecare includes the following individuals:<BR><BR>1. **Arvind Gupta** - Director (Finance) & CFO<BR>2. **Anil Kumar** - Independent Director<BR>3. **Ruby Bansal** - Independent Director<BR>4. **Parul Rai** - Company Secretary & Compliance Officer<BR>5. **Vijay Kumar Sharma** - Director & Chief Executive Officer<BR>6. **Sundeep Kumar Dhawan** - Managing Director<BR>7. **Richa Sharma** - Independent Director<BR>8. **Chandan Kumar** - Director & CFO<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Vikas Lifecare?

Vikas Lifecare's peers include Astal Lab, Agribio Spirits, Sakuma Exports, Sicagen India, Chandrima Mercan, Northern Spirits, and Stratmont Indus. In terms of management risk, growth, and capital structure, Vikas Lifecare ranks below average compared to its peers, with a 1-year return of -45.32%.

Peers: The peers of Vikas Lifecare are Astal Lab, Agribio Spirits, Sakuma Exports, Sicagen India, Chandrima Mercan, Northern Spirits, and Stratmont Indus.<BR><BR>Quality Snapshot: Excellent management risk is observed at Astal Lab and Chandrima Mercan, while Average management risk is found at Sicagen India, Sakuma Exports, Northern Spirits, and Stratmont Indus, and the rest. Below Average management risk is noted for Agribio Spirits, Vikas Lifecare, and Chandrima Mercan. In terms of growth, Excellent growth is seen at Astal Lab and Chandrima Mercan, while Average growth is found at Sicagen India, and the rest. Below Average growth is observed at Agribio Spirits, Sakuma Exports, and Vikas Lifecare. For capital structure, Excellent capital structure is noted at Chandrima Mercan, Good capital structure is found at Astal Lab, Agribio Spirits, Sakuma Exports, and Sicagen India, while Vikas Lifecare and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Chandrima Mercan at 100.52%, while the lowest is Sakuma Exports at -46.46%. Vikas Lifecare's own 1-year return is -45.32%, which is slightly better than Sakuma Exports. Additionally, Agribio Spirits, Sakuma Exports, Vikas Lifecare, Sicagen India, Chandrima Mercan, Northern Spirits, and Stratmont Indus all have negative six-month returns.

When is the next results date for Vikas Lifecare Ltd?

The next results date for Vikas Lifecare Ltd is February 7, 2026.

The next results date for Vikas Lifecare Ltd is scheduled for February 7, 2026.

How has been the historical performance of Vikas Lifecare?

Vikas Lifecare has experienced fluctuating financial performance, with net sales increasing to 480.02 Cr in March 2025, but profitability declining significantly, resulting in a net loss of -10.61 Cr. Despite growth in total assets, cash flow from operations has worsened, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Vikas Lifecare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Vikas Lifecare's net sales have generally increased, reaching 480.02 Cr in March 2025 from 445.75 Cr in March 2024, although it slightly decreased from 476.05 Cr in March 2023. The total operating income followed a similar trend, peaking at 480.02 Cr in March 2025. However, the total expenditure has also risen, amounting to 501.62 Cr in March 2025, which has led to an operating profit (PBDIT) of 4.36 Cr, a decline from 30.49 Cr in the previous year. The company reported a profit before tax of -6.95 Cr in March 2025, down from 17.58 Cr in March 2024, resulting in a profit after tax of -5.00 Cr. The consolidated net profit also fell to -10.61 Cr in March 2025 from 14.03 Cr in March 2024. The total assets of Vikas Lifecare increased to 724.76 Cr in March 2025, up from 554.70 Cr in March 2024, while total liabilities rose to 724.76 Cr from 554.70 Cr in the same period. Cash flow from operating activities showed a negative trend, with -222.00 Cr in March 2025 compared to -41.00 Cr in March 2024, indicating challenges in cash generation. Overall, while Vikas Lifecare has seen growth in sales and assets, profitability has been inconsistent, reflecting a complex financial landscape.

Is Vikas Lifecare overvalued or undervalued?

As of July 22, 2024, Vikas Lifecare is considered overvalued and risky, with a negative PE ratio of -46.72 and an EV to EBITDA of -25.23, significantly underperforming against the Sensex with a year-to-date return of -38.77%.

As of 22 July 2024, the valuation grade for Vikas Lifecare has moved from very expensive to risky, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE ratio of -46.72, an EV to EBITDA of -25.23, and a Price to Book Value of 0.89, which highlight the underlying financial challenges the company faces.<BR><BR>In comparison to its peers, Vikas Lifecare's valuation metrics are concerning, particularly when contrasted with industry standards. For instance, its PE ratio is significantly negative, while the EV to EBITDA ratio also reflects a troubling trend. Notably, the company has underperformed against the Sensex, with a year-to-date return of -38.77% compared to the Sensex's positive 5.56%. This performance further reinforces the notion that Vikas Lifecare is currently overvalued in the market.

What is the technical trend for Vikas Lifecare?

As of June 4, 2025, Vikas Lifecare's technical trend is bearish, supported by daily moving averages and Bollinger Bands, despite a mildly bullish weekly MACD, indicating a prevailing bearish market sentiment.

As of 4 June 2025, the technical trend for Vikas Lifecare has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength indicated by the daily moving averages and Bollinger Bands both signaling bearish trends. The weekly MACD shows a mildly bullish signal, but this is countered by the monthly MACD and KST both being bearish. The Dow Theory indicates a mildly bearish trend on the weekly timeframe, while the monthly shows no trend. Overall, the indicators suggest a prevailing bearish sentiment in the market for Vikas Lifecare.

Who are the top shareholders of the Vikas Lifecare?

The top shareholders of Vikas Lifecare include promoter Vikas Garg with 13.1%, public shareholder Sylph Technologies at 3.1%, and individual investors holding 73.79%. There are also 18 Foreign Institutional Investors with a combined 0.46% stake, and no mutual funds currently hold shares.

The top shareholders of Vikas Lifecare include Vikas Garg, who is the promoter with the highest holding at 13.1%. The highest public shareholder is Sylph Technologies, holding 3.1%. Additionally, individual investors collectively hold a significant portion of the shares at 73.79%. The company also has 18 Foreign Institutional Investors (FIIs) with a combined holding of 0.46%. Notably, there are no mutual funds currently holding shares in the company.

Has Vikas Lifecare declared dividend?

No Dividend History Available